Advertisement

Treatment of Type 2 Diabetes and Outcomes in Patients With Heart Failure: A Nested Case–Control Study From the U.K. General Practice Research Database

Table 2

Use of antidiabetic drugs and risk of mortality

Control subjects n = 1,633 Case subjects n = 1,633 Unadjusted OR (95% CI) Adjusted OR (95%CI)
Diabetes treatment in the 90 days prior to index date:
    No antidiabetic drugs 573 (35) 733 (45) Reference category
    Sulphonylurea monotherapy 391 (24) 362 (22) 0.73 (0.61–0.88) 0.84 (0.67–1.06)
    Metformin monotherapy 221 (14) 155 (9) 0.54 (0.42–0.68) 0.65 (0.48–0.87)
    Thiazolidinedione monotherapy 4 (0.2) 5 (0.3) 0.93 (0.24–3.53) 1.08 (0.23–5.07)
    Insulin monotherapy 89 (5) 141 (9) 1.19 (0.88–1.60) 1.24 (0.85–1.80)
    Combination therapy with insulin 76 (5) 46 (3) 0.47 (0.32–0.70) 0.72 (0.44–1.17)
    Combination oral therapy without insulin 279 (17) 191 (12) 0.52 (0.42–0.65) 0.74 (0.56–0.99)
Any use of diabetic drugs in the 90 days prior to index date (as monotherapy or as part of combination therapy):
    Any sulphonylurea 674 (41) 566 (35) 0.75 (0.65–0.87) 0.90 (0.75–1.08)
    Any metformin 529 (32) 349 (21) 0.55 (0.46–0.65) 0.72 (0.59–0.90)
    Any thiazolidinedione 59 (4) 40 (2) 0.64 (0.42–0.99) 0.92 (0.54–1.55)
    Any insulin 165 (10) 187 (11) 1.16 (0.92–1.45) 1.11 (0.83–1.50)
Covariates included in the multivariate models:
    Age (adjusted OR per year) 1.08 (1.03–1.13)
    Systolic BP (adjusted OR for <120 mmHg) 1.89 (1.48–2.40)
    Diastolic BP (adjusted OR for ≥90 mmHg) 0.96 (0.71–1.31)
    BMI (adjusted OR for ≥30) 0.67 (0.52–0.86)
    Hemoglobin (adjusted OR for <120 g/l) 1.76 (1.41–2.19)
    Hemoglobin A1C (adjusted OR for ≥8) 1.06 (0.77–1.46)
    GFR (adjusted OR for <30 ml · min−1 · kg−1) 2.04 (1.44–2.88)
    Hypertension 1.05 (0.87–1.26)
    Prior myocardial infarct or coronary revascularization 1.83 (1.49–2.25)
    Valvular heart disease 1.22 (0.91–1.63)
    Angina 1.02 (0.84–1.24)
    Atrial fibrillation 1.08 (0.87–1.34)
    Dyslipidemia 0.95 (0.73–1.22)
    Chronic obstructive lung disease 1.17 (0.93–1.48)
    Cerebrovascular disease 1.56 (1.27–1.90)
    Smoker (current or former) 0.84 (0.69–1.04)
    Peripheral vascular disease 1.01 (0.79–1.28)
    Cancer 1.94 (1.47–2.55)
    Dementia 1.25 (0.77–2.01)
    Peptic ulcer disease 1.01 (0.75–1.36)
Medication use within 90 days of index date:
    ACE inhibitor/ARB 0.55 (0.45–0.68)
    Aspirin 0.66 (0.55–0.80)
    Digoxin 0.74 (0.59–0.93)
    β-blocker 0.76 (0.61–0.95)
    Statin 0.59 (0.46–0.75)
    Spironolactone 1.20 (0.93–1.55)

  • Data are n (%) unless otherwise indicated. BP, blood pressure.

This Article

  1. Published online before print March 18, 2010, doi: 10.2337/dc09-2227 Diabetes Care June 2010 vol. 33 no. 6 1213-1218
  1. AbstractFree
  2. Full Text
  3. Full Text (PDF)
  4. Online Appendix

Current Issue

  1. February 2012, 35 (2)
  1. Current Issue
  1. Alert me to new issues of Diabetes Care
Advertisement